Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

First Posted Date
2021-10-13
Last Posted Date
2023-08-01
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
157
Registration Number
NCT05076942
Locations
🇺🇸

Duke Women's Cancer Care Raleigh, Raleigh, North Carolina, United States

🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 24 locations

HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers

First Posted Date
2021-10-13
Last Posted Date
2024-08-29
Lead Sponsor
Mayo Clinic
Target Recruit Count
174
Registration Number
NCT05075980
Locations
🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 6 locations

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

First Posted Date
2021-10-01
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
430
Registration Number
NCT05063552
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

Epic Care-Dublin, Dublin, California, United States

🇺🇸

Epic Care Partners in Cancer Care, Emeryville, California, United States

and more 150 locations

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

First Posted Date
2021-09-29
Last Posted Date
2024-12-19
Lead Sponsor
AstraZeneca
Target Recruit Count
630
Registration Number
NCT05061550
Locations
🇹🇷

Research Site, Izmir, Turkey

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

First Posted Date
2021-09-28
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
189
Registration Number
NCT05058651
Locations
🇺🇸

Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

🇺🇸

Kaiser Permanente-Anaheim, Anaheim, California, United States

and more 201 locations

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

First Posted Date
2021-09-20
Last Posted Date
2024-11-29
Lead Sponsor
NRG Oncology
Target Recruit Count
464
Registration Number
NCT05050162
Locations
🇺🇸

UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

🇺🇸

Mercy Cancer Center - Carmichael, Carmichael, California, United States

and more 349 locations

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

First Posted Date
2021-09-17
Last Posted Date
2024-11-28
Lead Sponsor
AstraZeneca
Target Recruit Count
450
Registration Number
NCT05048797
Locations
🇹🇷

Research Site, Çankaya, Turkey

Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma

Phase 2
Not yet recruiting
Conditions
Head and Neck Squamous Carcinoma
Interventions
Drug: Nedaplatin
Drug: Cisplatin
First Posted Date
2021-09-09
Last Posted Date
2021-09-09
Lead Sponsor
Guiyang Medical University
Target Recruit Count
164
Registration Number
NCT05039606
Locations
🇨🇳

The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

First Posted Date
2021-09-01
Last Posted Date
2021-09-01
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
53
Registration Number
NCT05030077
Locations
🇨🇳

Tianjin Medical Unversity Second Hospital, Tianjin, China

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

First Posted Date
2021-08-30
Last Posted Date
2023-07-19
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
60
Registration Number
NCT05026593
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy